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Dipyridamole. Recently, the Food and Drug Administra-
tion approved intravenous dipyridamole for pharmacologic 
vasodilation in conjunction with myocardial perfusion imag-
ing. This decision was long awaited by nuclear cardiologists 
and physicians. Extensive clinical experience for over a 
decade has established dipyridamole coronary vasodilation 
with thallium-201 imaging as an invaluable alternative to 
exercise testing for detecting coronary artery disease (1-3) 
and for risk stratification of cardiac and noncardiac patients 
(4-9). 
Adenosine: the present study. The coronary vasodilator 
effect of dipyridamole infusion is the indirect result of 
increased endogenous adenosine levels (10,11). Verani et al. 
(12) and Nguyen et al. (13) recently reported that it is feasible 
to infuse adenosine directly for use with thallium-201 imag-
ing. In this issue of the Journal. Coyne et al. (14) compare 
traditional exercise thallium-201 imaging with adenosine 
thallium-201 imaging in patients who also had coronary 
angiography. Adenosine was infused at a rate of 140 ltg/kg 
per min. After 3 minutes of infusion, thallium-201 was 
injected for tomographic imaging. The investigators demon-
strated a close agreement between the two modalities and 
virtually identical sensitivity. specificity and diagnostic ac-
curacy for detection of coronary artery disease. In their 
analysis the authors (14) did not specifically detail how the 
detection of reversible myocardial perfusion defects com-
pared in the two tests. However. separate analysis in pa-
tients without prior infarction suggests that there was no 
significant difference. The present and previous studies 
indicate that both adenosine and dipyridamole thallium-201 
imaging provide diagnostic information comparable with that 
of exercise thallium-201 imaging. However, no direct "head 
to head" comparative study with the two pharmaceutical 
agents in the same patients has as yet been performed. The 
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obvious question is,' Is there any reason to prefer either 
dipyridamole or adenosine for use with myocardial perfusion 
imaging? 
Heterogeneity of blood flow. Critical for detection of 
coronary artery disease by perfusion imaging with pharma-
cologic vasodilation is the creation of heterogeneity of 
myocardial blood flow. This can be achieved with both 
dipyridamole and adenosine because of a difference in 
coronary reserve in the vascular bed distal to a critical 
coronary stenosis and that supplied by normal coronary 
arteries (15). In the presence of a functionally significant 
coronary stenosis, autoregulatory mechanisms preserve nu-
trient blood flow at rest by dilation of coronary resistance 
vessels (coronary reserve). Consequently, because coronary 
reserve is already partially or completely recruited, pharma-
cologic vasodilation will have either no or only minimal 
effect on increasing regional myocardial blood flow. In 
contrast, in the vascular bed distal to normal epicardial 
vessels, recruitment of total coronary reserve can result in a 
3- to 5-fold increase in regional myocardial blood flow. This 
marked heterogeneity of the distribution of myocardial blood 
flow can be visualized with gamma cameras using radioac-
tive myocardial perfusion imaging agents. 
Duration and degree of vasodilator effect. The vasodilator 
effect of dipyridamole is prolonged, up to :::0:20 min (16,17), 
whereas the effect of adenosine is extremely short, with an 
effective half-life of 30 s (18). The vasodilator response after 
dipyridamole infusion has been shown to be variable (19,20), 
whereas recruitment of coronary reserve by adenosine infu-
sion appears to be consistent and near maximal (18). This 
finding is in agreement with the clinical observation that side 
effects with dipyridamole are relatively mild and few in 
comparison with those associated with adenosine. 
These differences in pharmacologic effect should be con-
sidered with regard to specific clinical applications. The 
prolonged effect of dipyridamole would be particularly use-
ful in combination with imaging protocols and technologies 
that are not easily combined with simultaneous physical 
exercise. For example, dipyridamole infusion is conceivably 
more practical than adenosine in combination with positron 
emission tomography. Similarly, when vasodilation is con-
sidered with nuclear magnetic resonance imaging, dipyrida-
mole would be more practical. 
Some investigators (22) have advocated combining phar-
macologic vasodilation with subsequent low level physical 
exercise. This is indeed feasible after dipyridamole infusion; 
however, it may be difficult to continue adenosine infusion 
while the patient exercises. 
The short-lasting effect of adenosine may be advanta-
geous when rapid serial assessments of myocardial blood 
flow are to be made. For example, by using short-lived 
positron emitters (such as rubidium-82, nitrogen-13. oxy-
gen-IS labeled water) or radiopharmaceutical agents that 
clear rapidly from the heart (such as technetium-99m 
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teboroxime), short-lasting vasodilation with adenosine 
would allow repeat imaging sequences. 
The apparent moderate vasodilator effect of dipyrida-
mole is not necessarily a disadvantage. Myocardial uptake of 
imaging agents with relatively low (60% to 80%) extraction 
fraction (such as rubidium-82. nitrogen- 13. thallium-20l or 
technetium-99m SestaMIBl) show a linear relation with 
myocardial blood flow only in the low to moderate flow 
range (22-24). At high flow levels the correlation is subopti-
mal. Therefore. use of these radiotracers' maximal vasodi-
lator effect, as can be achieved with adenosine, will not 
result in better and more accurate imaging data. On the other 
hand, myocardial perfusion imaging agents with a high 
myocardial extraction fraction (such as oxygen-IS labeled 
water and technetium-99m teboroxime) show a linear rela-
tion with myocardial blood flow even at very high flow levels 
(25,26). Therefore, the latter radiotracers may be more 
suitable for use in conjunction with adenosine infusion. 
Clinical implications. Which of the two pharmaceuticals 
is preferable for clinical myocardial perfusion imaging will be 
determined by the imaging technology. imaging protocols 
and imaging agents employed. Dipyridamole infusion has an 
established record of clinical safety with a relatively low 
incidence of side effects and proved clinical usefulness. 
Adenosine infusion requires close patient monitoring by 
trained clinical staff. Whereas serious adverse reactions with 
adenosine usually can be managed by simply discontinuing 
the infusion, serious side effects with dipyridamole are not 
always easily converted because of its prolonged vasodilator 
effect. Thus, the same close supervision and ability to meet 
emergencies that is required for physical exercise testing 
should be provided when pharmacologic vasodilation IS 
performed with either pharmaceutical agent. 
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